Mesulergine (CU32‐085) in the treatment of Parkinson's disease

Ronald F. Pfeifer, Kathleen Wilken, Carolyn Glaeske

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Twenty patients with Parkinson's disease were treated with the 8‐α‐ergoline derivative mesulergine. Participants were divided into two groups, and over a nine‐week period, mesulergine dosage was increased to amaximum of either 10 or 20 mg daily. During this time levodopa‐carbidopa (LD‐CD) dosage was reduced and treatement was discontinued if possible. The dosage of LD‐CD was reduced 75% in the 10 mg group and 74% in the 20 mg group. Patients in the low dose group maintained in each of the cardinal signs of parkinsonism. Adverse effects were generally mild and infrequent. Many adverse effects induced by LD‐CD diminished or resolved. Our results suggest that mesulergine can be valuable in the management of Parkinson's disease, particularly in those individuals experiencing dose‐limiting adverse effects from LD‐CD.

Original languageEnglish (US)
Pages (from-to)334-336
Number of pages3
JournalAnnals of Neurology
Volume17
Issue number4
DOIs
StatePublished - Apr 1985

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Mesulergine (CU32‐085) in the treatment of Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this